Key result
High platelet-fibrin clot strength (≥68 mm) significantly increased the risk of postprocedural coronary microvascular dysfunction in acute myocardial infarction (OR 4.35; 95% CI 1.74-10.89).
Why the study?
The association between thrombogenicity and coronary microvascular dysfunction has been poorly explored in patients with acute myocardial infarction.
Does high platelet-fibrin clot strength increase the risk of coronary microvascular dysfunction and ischemic events in patients with acute myocardial infarction?
Observational (n=116)
Does high platelet-fibrin clot strength increase the risk of coronary microvascular dysfunction and ischemic events in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Heightened thrombogenicity, specifically high platelet-fibrin clot strength, is strongly associated with postprocedural coronary microvascular dysfunction and increased ischemic events in patients with acute myocardial infarction.
The association between thrombogenicity and coronary microvascular dysfunction (CMD) has been poorly explored in patients with acute myocardial infarction (AMI). In our real-world clinical practice (N = 116), thrombogenicity was evaluated with thromboelastography and conventional hemostatic measures, and CMD was defined as index of microcirculatory resistance of >40 U using the invasive physiologic test. High platelet-fibrin clot strength (P-FCS) (≥68 mm) significantly increased the risk of postprocedural CMD (odds ratio: 4.35; 95% CI: 1.74-10.89). Patients with both CMD and high P-FCS had a higher rate of ischemic events compared to non-CMD subjects with low P-FCS (odds ratio: 5.58; 95% CI: 1.31-23.68). This study showed a close association between heightened thrombogenicity and CMD and their prognostic implications after reperfusion in acute myocardial infarction patients.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2021) conducted an observational in Acute Myocardial Infarction (n=116). High platelet-fibrin clot strength (≥68 mm) vs. Low platelet-fibrin clot strength was evaluated on Postprocedural coronary microvascular dysfunction (index of microcirculatory resistance >40 U) (OR 4.35, 95% CI 1.74-10.89). High platelet-fibrin clot strength (≥68 mm) significantly increased the risk of postprocedural coronary microvascular dysfunction in acute myocardial infarction (OR 4.35; 95% CI 1.74-10.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: